tiprankstipranks

Enfusion downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley analyst Michael Infante downgraded Enfusion (ENFN) to Equal Weight from Overweight with a price target of $11.25, up from $11. With Clearwater Analytics’ (CWAN) proposed acquisition of Enfusion at $11.25 per share, strategic value has been unlocked in Enfusion shares, the analyst tells investors in a research note. The firm says the acquisition accelerates shareholder value realization and renders historical issues obsolete.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue